Skip to Main Content

Advertisement

Skip Nav Destination

NK Cell Therapies Battle Hematologic Malignancies

July 7, 2022

Mid-July 2022

Phase I data from independent dose-finding studies of NKX101 and NKX019, two chimeric antigen receptor (CAR) natural killer (NK) cell therapy candidates, showed potential for treating hematologic malignancies. The study findings were announced in a press release by Nkarta Inc., the biopharmaceutical company that developed the therapies.

In the trial of NKX101 in relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndromes, three of five patients with heavily pre-treated AML who received the higher dose level in a three-dose regimen achieved a complete response (CR) with hematologic recovery, with two of the three responses being measurable residual disease-negative.

In the trial of NKX019 in R/R B-cell malignancies, 13 patients who received study treatment were assessed. Five of six patients with non-Hodgkin lymphoma (NHL) who received three doses of 1 billion cells achieved a response (83% overall response rate [ORR]), and three of six achieved CR. For all cohorts in the dose-finding portion, seven of 10 evaluable patients with NHL achieved an objective response (70% ORR) and four of 10 achieved CR. Three patients with acute lymphoblastic leukemia were treated, with no response observed. In both trials, no dose-limiting toxicity was observed and there were no CAR T-like adverse events of any grade.

Source: Globe Newswire, April 25, 2022.

Advertisement

Connect with us:

CURRENT ISSUE
May 2024

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement